CARB-X IS FUNDING NOVEL MICRODEVICES TO DEVELOP A RAPID AND PORTABLE DIAGNOSTIC FOR SEXUALLY TRANSMITTED DISEASES INCLUDING ANTIBIOTIC-RESISTANT INFECTIONS
ARB-X is awarding Novel Microdevices, Inc. of Baltimore, Maryland, USA, up to $3.6 million in non-dilutive funding, and, subject to available funding, up to an additional $10.2 million if certain project milestones are met, to develop a new rapid molecular test to diagnose sexually-transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae. Novel’s new device would diagnose infections in about 25 minutes from a vaginal swab or urine sample, and detect antibiotic-resistant bacteria, including those resistant to ciprofloxacin and 3rd generation cephalosporins, the only antibiotics that are still effective as treatments for most strains of the gonorrhoeae bacteria.
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!